
Intellia Jumps After Gene-Editing Therapy Succeeds in Pivotal Trial for Rare Swelling Disorder
Intellia Therapeutics rose sharply after reporting successful late-stage results for its experimental gene-editing treatment for hereditary angioedema, a rare disorder that




















